Suppr超能文献

益生菌与胃肠道疾病:临床证据与基础科学

Probiotics and Gastrointestinal Disease: Clinical Evidence and Basic Science.

作者信息

Petrof Elaine O

机构信息

Department of Medicine, GIDRU and Division of Infectious Diseases, Queen's University, Kingston, ON Canada.

出版信息

Antiinflamm Antiallergy Agents Med Chem. 2009 Sep 1;8(3):260-269. doi: 10.2174/187152309789151977.

Abstract

Our intestinal microbiota serve many roles vital to the normal daily function of the human gastrointestinal tract. Many probiotics are derived from our intestinal bacteria, and have been shown to provide clinical benefit in a variety of gastrointestinal conditions. Current evidence indicates that probiotic effects are strain-specific, they do not act through the same mechanisms, and nor are all probiotics indicated for the same health conditions. However, they do share several common features in that they exert anti-inflammatory effects, they employ different strategies to antagonize competing microorganisms, and they induce cytoprotective changes in the host either through enhancement of barrier function, or through the upregulation of cytoprotective host proteins. In this review we focus on a few selected probiotics - a bacterial mixture (VSL#3), a Gram-negative probiotic (E. coli Nissle 1917), two Gram-positive probiotic bacteria (LGG, L. reuteri), and a yeast probiotic (S. boulardii) - for which sound clinical and mechanistic data is available. Safety of probiotic formulations is also discussed.

摘要

我们的肠道微生物群对人类胃肠道的正常日常功能起着许多至关重要的作用。许多益生菌来源于我们的肠道细菌,并且已被证明在多种胃肠道疾病中具有临床益处。目前的证据表明,益生菌的作用具有菌株特异性,它们并非通过相同的机制发挥作用,也并非所有益生菌都适用于相同的健康状况。然而,它们确实具有几个共同特征,即发挥抗炎作用、采用不同策略对抗竞争性微生物,并且它们通过增强屏障功能或上调宿主细胞保护蛋白在宿主中诱导细胞保护变化。在本综述中,我们重点关注几种选定的益生菌——一种细菌混合物(VSL#3)、一种革兰氏阴性益生菌(大肠杆菌Nissle 1917)、两种革兰氏阳性益生菌(LGG、罗伊氏乳杆菌)和一种酵母益生菌(布拉酵母菌)——针对这些益生菌有可靠的临床和机制数据。还讨论了益生菌制剂的安全性。

相似文献

1
Probiotics and Gastrointestinal Disease: Clinical Evidence and Basic Science.
Antiinflamm Antiallergy Agents Med Chem. 2009 Sep 1;8(3):260-269. doi: 10.2174/187152309789151977.
2
Probiotics, prebiotics, and synbiotics.
Adv Biochem Eng Biotechnol. 2008;111:1-66. doi: 10.1007/10_2008_097.
4
Probiotic Properties of Escherichia coli Nissle in Human Intestinal Organoids.
mBio. 2020 Jul 7;11(4):e01470-20. doi: 10.1128/mBio.01470-20.
5
Probiotics in digestive diseases: focus on Lactobacillus GG.
Minerva Gastroenterol Dietol. 2015 Dec;61(4):273-92.
7
Safety of probiotic Escherichia coli strain Nissle 1917 depends on intestinal microbiota and adaptive immunity of the host.
Infect Immun. 2010 Jul;78(7):3036-46. doi: 10.1128/IAI.00218-10. Epub 2010 Apr 26.
9
A survey of multiple candidate probiotic bacteria reveals specificity in the ability to modify the effects of key wound pathogens.
Microbiol Spectr. 2024 Jun 4;12(6):e0034724. doi: 10.1128/spectrum.00347-24. Epub 2024 May 3.
10
Effect of probiotic strains on interleukin 8 production by HT29/19A cells.
Am J Gastroenterol. 2002 May;97(5):1182-6. doi: 10.1111/j.1572-0241.2002.05693.x.

引用本文的文献

2
Bee Pollen as Functional Food: Insights into Its Composition and Therapeutic Properties.
Antioxidants (Basel). 2023 Feb 23;12(3):557. doi: 10.3390/antiox12030557.
3
Lactic Acid Bacteria Mixture Isolated From Wild Pig Alleviated the Gut Inflammation of Mice Challenged by .
Front Immunol. 2022 Jan 26;13:822754. doi: 10.3389/fimmu.2022.822754. eCollection 2022.
6
Effects of Escherichia coli strain Nissle 1917 on exercise-induced disruption of gastrointestinal integrity.
Eur J Appl Physiol. 2020 Jul;120(7):1591-1599. doi: 10.1007/s00421-020-04382-w. Epub 2020 May 12.
7
Microbial-Based and Microbial-Targeted Therapies for Inflammatory Bowel Diseases.
Dig Dis Sci. 2020 Mar;65(3):757-788. doi: 10.1007/s10620-020-06090-z.
10
The Role of Probiotics in the Treatment of Dysentery: a Randomized Double-Blind Clinical Trial.
Probiotics Antimicrob Proteins. 2017 Dec;9(4):380-385. doi: 10.1007/s12602-017-9271-0.

本文引用的文献

2
Defensins and inflammation: the role of defensins in inflammatory bowel disease.
J Gastroenterol Hepatol. 2009 Feb;24(2):202-8. doi: 10.1111/j.1440-1746.2008.05772.x.
3
The search for disease-associated compositional shifts in bowel bacterial communities of humans.
Trends Microbiol. 2008 Oct;16(10):488-95. doi: 10.1016/j.tim.2008.07.005. Epub 2008 Sep 8.
4
Probiotics for prevention of antibiotic-associated diarrhea.
J Clin Gastroenterol. 2008 Jul;42 Suppl 2:S58-63. doi: 10.1097/MCG.0b013e3181618ab7.
5
Recommendations for probiotic use--2008.
J Clin Gastroenterol. 2008 Jul;42 Suppl 2:S104-8. doi: 10.1097/MCG.0b013e31816b903f.
6
Ecological role of lactobacilli in the gastrointestinal tract: implications for fundamental and biomedical research.
Appl Environ Microbiol. 2008 Aug;74(16):4985-96. doi: 10.1128/AEM.00753-08. Epub 2008 Jun 6.
7
Probiotic Lactobacillus reuteri suppress proinflammatory cytokines via c-Jun.
Inflamm Bowel Dis. 2008 Aug;14(8):1068-83. doi: 10.1002/ibd.20448.
8
Human-derived probiotic Lactobacillus reuteri demonstrate antimicrobial activities targeting diverse enteric bacterial pathogens.
Anaerobe. 2008 Jun;14(3):166-71. doi: 10.1016/j.anaerobe.2008.02.001. Epub 2008 Feb 29.
10
Probiotics ameliorate the hydrogen peroxide-induced epithelial barrier disruption by a PKC- and MAP kinase-dependent mechanism.
Am J Physiol Gastrointest Liver Physiol. 2008 Apr;294(4):G1060-9. doi: 10.1152/ajpgi.00202.2007. Epub 2008 Feb 21.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验